title: Cellular immune response evaluation of cutaneous leishmaniasis patients cells stimulated with Leishmania (Viannia) braziliensis antigenic fractions before and after clinical cure.
abstract: American cutaneous leishmaniasis (ACL) is a disease where susceptibility or resistance is dependent on T cell response. This is characterized by an increased in CD4⁺ T cells, capable of inducing opposite disease profiles, and CD8⁺ T cells, that are related to immuno protection. We characterized T lymphocytes from patients before and after treatment, patients that spontaneously healed and controls, also evaluating their production of IL-10, IL-4, TNF-α and IFN-γ, after stimulation with soluble/insoluble antigenic fractions of Leishmania (Viannia) braziliensis. We observed the production of suppressive cytokines in the early phase of leishmaniasis with significant presence CD4⁺ T cells, suggesting their connection with disease progression. After healing, the immune pattern observed was a type 1 response, what seems to be associated with cure and/or protection in the ACL. The results also showed that both fractions induced a specific immune response, contributing to the search for relevant antigens in this disease.
authors.affiliation: Departamento de Imunologia, Centro de Pesquisas Aggeu Magalhães-CPqAM/FIOCRUZ, Recife, PE, Brazil. carolina.brelaz@gmail.com
authors.forename: Maria Carolina Accioly
authors.initials: MC
authors.lastname: Brelaz-de-Castro
authors.forename: Amanda Ferreira
authors.initials: AF
authors.lastname: de Almeida
authors.forename: Andresa Pereira
authors.initials: AP
authors.lastname: de Oliveira
authors.forename: Marina
authors.initials: M
authors.lastname: de Assis-Souza
authors.forename: Lucas Ferreira
authors.initials: LF
authors.lastname: da Rocha
authors.forename: Valéria Rêgo Alves
authors.initials: VR
authors.lastname: Pereira
mesh_terms: D000953:Antigens, Protozoan / Q000276:immunology; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000469:parasitology; D002478:Cells, Cultured; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D016753:Interleukin-10 / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D007892:Leishmania braziliensis / Q000276:immunology*; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy / Q000276:immunology*; D008536:Meglumine / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D000953:Antigens, Protozoan; D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D015847:Interleukin-4; D008536:Meglumine; D000077485:Meglumine Antimoniate; D007371:Interferon-gamma